Blood Test Reads Thyroid Hormone Metabolites to Flag Cancerous Nodules

Thyroid nodules are extraordinarily common. Depending on the population screened and the sensitivity of the imaging used, they are detected in roughly 60 to 70 percent of the general population, yet only about 5 to 10 percent of them turn out to be malignant. That gap between how often nodules are found and how rarely they matter has long defined the central dilemma of thyroid medicine: clinicians must sort a vast pool of mostly harmless lumps into the small fraction that harbor cancer, and they must do so without subjecting millions of patients to unnecessary surgery. A new study published in Cell Research by Mengzhe Guo, Houfa Geng, Jun Liang, Mingzhao Xing and colleagues, writing for the THMs Group, proposes an unexpected way to make that sorting easier — by reading the chemical fingerprints of thyroid hormone metabolism circulating in a patient’s blood.

The logic behind the approach rests on a simple biological premise. Thyroid follicular cells do not merely produce thyroxine and triiodothyronine; they also metabolize these hormones through a network of deiodinases, sulfotransferases, glucuronidation pathways and other enzymatic steps. Cancerous transformation rewrites cellular metabolism wholesale, and there is no reason to expect that the handling of thyroid hormones would be spared. If malignant nodules process thyroid hormone differently from benign ones, the downstream metabolites released into the bloodstream should carry a detectable signature. The researchers set out to test whether that signature could be captured with liquid chromatography–mass spectrometry, a technique sensitive enough to quantify trace metabolites in serum with high precision.

To appreciate why such a test is needed, it helps to review how thyroid nodules are evaluated today. The diagnostic pathway typically begins with neck ultrasonography, interpreted through the American College of Radiology’s Thyroid Imaging Reporting and Data System, known as ACR TI-RADS. This system assigns nodules to one of five incremental categories, from 1 to 5, with categories 1 and 2 indicating benign or non-suspicious findings and category 5 flagging nodules that are highly suspicious for malignancy. Sonography is cheap, noninvasive and widely available, but it is anatomic rather than molecular: it describes what a nodule looks like, not what it is. Overlapping features between benign and malignant lesions mean that many nodules land in an uncertain middle ground.

The second pillar of diagnosis is fine-needle aspiration biopsy, in which cells are drawn from the nodule and examined under a microscope. Results are reported through the Bethesda System for Reporting Thyroid Cytopathology, or TBSRTC, which comprises six diagnostic categories, each tied to an estimated risk of malignancy. Category I is non-diagnostic, category II is benign, category III is atypia of undetermined significance, category IV is follicular neoplasm, category V is suspicious for malignancy and category VI is malignant. For patients in categories V and VI, surgery is usually straightforward. The trouble lies in categories III and IV — the cytologically indeterminate nodules that account for 25 to 30 percent of biopsy results and pose what the authors describe as a major diagnostic challenge in current thyroid nodule management.

Indeterminate nodules create a cascade of clinical anxiety and overtreatment. Because cytology cannot reliably distinguish a benign follicular lesion from a follicular carcinoma, many patients with Bethesda III or IV results undergo diagnostic surgery — a hemithyroidectomy performed largely to obtain a definitive histopathological answer. The majority of those operations, by most estimates, remove nodules that turn out to be benign. Each unnecessary surgery carries real costs: general anesthesia, a scar on the neck, a small risk of injury to the recurrent laryngeal nerve or the parathyroid glands, and, for some patients, lifelong thyroid hormone replacement. Molecular tests performed on biopsy material have improved triage in recent years, but they require adequate cellular material, add expense, and still leave a residue of uncertainty. A test that works on serum — a simple blood draw independent of the biopsy — would sidestep several of these limitations at once.

That is precisely the niche the THM test is designed to occupy. The study, registered in the Chinese Clinical Trial Registry under identifier ChiCTR2300070912 and approved by the ethics committees of participating centers including Xuzhou Central Hospital, Liyang People’s Hospital, the First Affiliated Hospital of Anhui Medical University, Fudan University Cancer Center and Shandong First Medical University Affiliated Endocrine and Metabolic Disease Hospital, enrolled patients with thyroid nodules across multiple hospitals in China. All participants provided informed consent. Serum samples were collected before surgical pathology was known, and the concentrations of thyroid hormone metabolites were measured by liquid chromatography coupled to tandem mass spectrometry, a gold-standard analytical platform for targeted metabolomics.

The analytical workflow matters as much as the biology. Targeted metabolomics of thyroid hormones and their derivatives is technically demanding because these iodinated compounds exist at very low concentrations in blood, bind to carrier proteins, and are chemically similar to one another. The research team, with Guo, Zang, Zou and Peng performing the LC-MS analysis, had to resolve closely related molecular species — the various deiodinated, sulfated and conjugated forms of T4 and T3 — and quantify them reproducibly across hundreds of clinical samples. Data analysis, led by Guo, Sun and Liu, then searched for metabolite patterns that separated malignant from benign nodules, ultimately distilling the measurements into a diagnostic test intended to complement, rather than replace, existing tools.

The clinical vision that emerges from the paper is a layered diagnostic algorithm. Ultrasonography would continue to serve as the first filter, identifying nodules that warrant biopsy. Fine-needle aspiration would continue to provide cytology, and for the substantial fraction of results that fall into Bethesda categories III and IV, the serum THM test would offer an additional, independent line of molecular evidence drawn from the patient’s blood. Because the test interrogates systemic hormone metabolism rather than a handful of cells on a slide, it captures tumor biology that cytology and even many DNA- and RNA-based molecular panels do not directly measure. The authors frame the test as a tool for the molecular diagnostic evaluation of thyroid nodules — a way to convert an indeterminate cytology result into a more confident decision about whether surgery is truly necessary.

Several features of the study strengthen its credibility. The work was a multi-center collaboration spanning endocrinology, thyroid surgery, head and neck surgery, ultrasound and pharmacy departments, with sample collection performed by Geng, Wan, Zhou, Song, Liao and Xi across hospitals in Jiangsu, Anhui, Shanghai and Shandong provinces. The study was conceived and supervised by Liang, Xing and Wang, and the manuscript was drafted by Guo and Geng with editing from Liang and Xing. The authors declare no competing interests, and the work received support from the National Natural Science Foundation of China, the Natural Science Foundation of Jiangsu Province, the Science and Technology Commission of Shanghai Municipality and several regional programs. The publication appears as a letter to the editor in Cell Research, a format that typically presents a focused, complete finding rather than an exhaustive monograph, and the published figure summarizes the study design and the test’s performance in the differential diagnosis of thyroid nodules.

The broader significance of this work extends beyond the thyroid. Metabolomics is increasingly recognized as a rich source of liquid-biopsy information, complementing the circulating DNA and RNA markers that have dominated the molecular diagnostics conversation. Thyroid hormone metabolites offer a uniquely attractive analyte class for thyroid nodules because they are organ-specific by definition: only thyroid tissue makes thyroid hormones, so changes in their metabolic profile point directly to perturbations in thyroid physiology. If the THM test’s performance holds up in independent cohorts and in routine clinical use, patients facing the most common and most frustrating biopsy result in thyroid medicine — an indeterminate nodule — could one day get a clearer answer from a vial of blood, sparing many of them an operation they never needed. For a disease detected in nodules found in up to seventy percent of adults, that would be no small thing.

Subject of Research: A serum thyroid hormone metabolite test for molecular diagnostic evaluation of thyroid nodules

Article Title: A serum thyroid hormone metabolite test for molecular diagnostic evaluation of thyroid nodules

Article References: Guo, M., Geng, H., Sun, Q., Wan, H., Zhou, P., Song, Y., Zou, C., Zang, X., Xi, H., Liao, T., Liu, X., Peng, G., Wang, Y., Xing, M., Liang, J., for the “THMs Group”, Liang, J., Geng, H., Liu, X., … Zhou, P. (2026). A serum thyroid hormone metabolite test for molecular diagnostic evaluation of thyroid nodules. Cell Research. https://doi.org/10.1038/s41422-026-01300-1

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01300-1

Keywords: thyroid nodules, thyroid cancer, thyroid hormone metabolites, metabolomics, liquid biopsy, fine-needle aspiration biopsy, Bethesda System, ACR TI-RADS, molecular diagnostics, LC-MS, differentiated thyroid cancer, Cell Research